Results 231 to 240 of about 451,573 (269)

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives

American Journal of Hematology, EarlyView.
ABSTRACT Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK–STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as ...
Giuseppe G. Loscocco, Paola Guglielmelli
wiley   +1 more source

The effect on the equilibrium sickle cell allele frequency of the probable protection conferred by malaria and sickle cell gene against other infectious diseases. [PDF]

Sci Rep
Habibzadeh F.
europepmc   +1 more source

Comparison of statistical power between 2×2 allele frequency and allele positivity tables in case‐control studies of complex disease genes [PDF]

, 2001
Jun Ohashi, Shuji Yamamoto, Nobuatsu TSUCHIYA, Yuki HATTA, Tae Komata, Michio M. Matsushita, Katsusi Tokunaga   +6 more
openalex   +1 more source

Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review

American Journal of Hematology, EarlyView.
ABSTRACT Allogeneic hematopoietic stem‐cell transplantation (HCT) remains the only potentially curative therapy for patients with myelodysplastic neoplasms (MDS) and myelofibrosis (MF) and is the standard care for eligible patients with higher‐risk disease. Despite significant advancements, both diseases pose unique challenges due to their clinical and
Nico Gagelmann, Nicolaus Kröger
wiley   +1 more source

The contribution of gene flow, selection, and genetic drift to five thousand years of human allele frequency change. [PDF]

Proc Natl Acad Sci U S A
Simon A, Coop G.
europepmc   +1 more source

ALFRED: an allele frequency database for diverse populations and DNA polymorphisms--an update [PDF]

, 2001
Michael V. Osier
openalex   +1 more source

Topics of Interest in Women With Myeloproliferative Neoplasms

American Journal of Hematology, EarlyView.
Women with MPN: life‐cycle phases, specific risks, and influencing factors. ABSTRACT Overview Sex and gender have emerged as central modifiers of disease biology, phenotype, and clinical outcomes in myeloproliferative neoplasms (MPNs). This review will uniquely highlight issues affecting women with MPN and articulate their relevant determinants ...
Natasha Szuber, Paola Guglielmelli, Naseema Gangat   +2 more
wiley   +1 more source

Germline BRCA2 variant with low variant allele frequency detected in tumor-only comprehensive genomic profiling. [PDF]

Cancer Sci
Hayashi H, Kunimasa K, Tanishima S, Nakamura K, Ishikawa M, Kato Y, Aimono E, Kawano R, Nishihara H.   +8 more
europepmc   +1 more source

Clonal Hematopoiesis and Thrombosis

American Journal of Hematology, EarlyView.
ABSTRACT Clonal hematopoiesis (CH) has been the focus of many research efforts in the last years and has emerged as a risk modifier for cardiovascular disease morbidity and mortality. While substantial evidence has accumulated regarding its impact on arterial system diseases, the connection with venous thrombosis has only recently been explored.
Cornelia Englisch, Cihan Ay
wiley   +1 more source

Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumors. [PDF]

Mol Oncol
Kalashnikova E, Aushev VN, Malashevich AK, Tin A, Krinshpun S, Salari R, Scalise CB, Ram R, Malhotra M, Ravi H, Sethi H, Sanchez S, Hagelstrom RT, Brevnov M, Rabinowitz M, Moshkevich S, Zimmermann BG, Liu MC, Aleshin A.   +18 more
europepmc   +1 more source